Ocriplasmin

Drug Profile

Ocriplasmin

Alternative Names: A 01016; Jejetrea®; Jetrea; Microplasmin; Recombinant human microplasmin; Recombinant microplasmin; THR 409

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Leuven
  • Developer Alcon; ThromboGenics; University of Leuven
  • Class Anti-ischaemics; Eye disorder therapies; Peptide fragments; Serine endopeptidases
  • Mechanism of Action Antiplasmin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral arterial occlusive disorders; Retinal disorders
  • New Molecular Entity Yes
  • Available For Licensing Yes - Thrombosis

Highest Development Phases

  • Marketed Retinal disorders
  • Phase II Diabetic retinopathy
  • Preclinical Retinal vein occlusion
  • Suspended Deep vein thrombosis; Peripheral arterial occlusive disorders; Stroke
  • Discontinued Age-related macular degeneration; Diabetic macular oedema

Most Recent Events

  • 28 Sep 2017 ThromboGenics launches 'already-diluted' formulation of Ocriplasmin for the treatment of retinal disorders, in USA
  • 18 Sep 2017 ThromboGenics to regain global rights of ocriplasmin from Alcon
  • 08 Jun 2016 Office of Biotechnology Products of the US FDA approves already diluted formulation of ocriplasmin for treatment of Retinal disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top